(Q47572351)

4 February 2018

title

Immunotherapy for psoriasis: from serendipity to selectivity. (English)

1 reference

4 February 2018

1 reference

Christopher Griffiths

series ordinal

1

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 January 2002

1 reference

4 February 2018

published in

The Lancet

1 reference

4 February 2018

volume

359

1 reference

4 February 2018

page(s)

279-280

1 reference

4 February 2018

issue

9303

1 reference

4 February 2018

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

T cells involved in psoriasis vulgaris belong to the Th1 subset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Expression of interleukin-12 is increased in psoriatic skin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2907536-0

7 January 2021

10.1016/S0140-6736(02)07536-0

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

11830192

1 reference

4 February 2018